Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report)'s share price was down 4.1% during trading on Thursday . The company traded as low as $9.23 and last traded at $9.38. Approximately 328,591 shares were traded during trading, a decline of 78% from the average daily volume of 1,464,205 shares. The stock had previously closed at $9.78.
Ginkgo Bioworks Trading Down 3.8%
The business has a 50-day moving average price of $7.61 and a two-hundred day moving average price of $9.09. The stock has a market capitalization of $523.22 million, a P/E ratio of -0.68 and a beta of 1.25.
Ginkgo Bioworks (NYSE:DNA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.35). The company had revenue of $48.32 million during the quarter, compared to analyst estimates of $38.70 million. Ginkgo Bioworks had a negative net margin of 298.78% and a negative return on equity of 58.54%. On average, sell-side analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE raised its stake in Ginkgo Bioworks by 780.6% in the fourth quarter. Bank of America Corp DE now owns 3,764,455 shares of the company's stock valued at $36,967,000 after purchasing an additional 3,336,964 shares in the last quarter. Erste Asset Management GmbH raised its stake in Ginkgo Bioworks by 123.2% in the first quarter. Erste Asset Management GmbH now owns 1,650,000 shares of the company's stock valued at $9,405,000 after purchasing an additional 910,668 shares in the last quarter. Millennium Management LLC raised its stake in Ginkgo Bioworks by 113.1% in the first quarter. Millennium Management LLC now owns 1,427,600 shares of the company's stock valued at $8,137,000 after purchasing an additional 757,535 shares in the last quarter. Forbes J M & Co. LLP raised its stake in Ginkgo Bioworks by 56.0% in the first quarter. Forbes J M & Co. LLP now owns 1,094,564 shares of the company's stock valued at $6,239,000 after purchasing an additional 392,832 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in Ginkgo Bioworks by 25.4% in the first quarter. Goldman Sachs Group Inc. now owns 686,767 shares of the company's stock valued at $3,915,000 after purchasing an additional 139,126 shares in the last quarter. Institutional investors and hedge funds own 78.63% of the company's stock.
About Ginkgo Bioworks
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Featured Stories
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
